ZOMETA Drug Patent Profile

When do Zometa patents expire, and when can generic versions of Zometa launch?

Zometa is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has twenty-six patent family members in twenty-two countries.

The generic ingredient in ZOMETA is zoledronic acid. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zoledronic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zometa

A generic version of ZOMETA was approved as zoledronic acid by DR REDDYS LABS LTD on March 4^th, 2013.

Summary for ZOMETA

International Patents:	26
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	113
Patent Applications:	3,172
Drug Prices:	Drug price information for ZOMETA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZOMETA
DailyMed Link:	ZOMETA at DailyMed

See drug prices for ZOMETA

Recent Clinical Trials for ZOMETA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	Phase 3
Australian and New Zealand Intensive Care Research Centre	Phase 2
Lithuanian University of Health Sciences	N/A

See all ZOMETA clinical trials

Paragraph IV (Patent) Challenges for ZOMETA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOMETA	Injection	zoledronic acid	4 mg/100 mL, 100 mL vial	021223	1	2012-01-31
ZOMETA	Injection	zoledronic acid	0.8 mg (base) /mL	021223	1	2008-06-11

US Patents and Regulatory Information for ZOMETA

ZOMETA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-001	Aug 20, 2001		DISCN	Yes	No
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003		DISCN	Yes	No
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-003	Jun 17, 2011		DISCN	Yes	No	7,932,241		Y

Expired US Patents for ZOMETA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-001	Aug 20, 2001	4,777,163
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003	4,777,163

EU/EMA Drug Approvals for ZOMETA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Zoledronic Acid Accord	zoledronic acid	EMEA/H/C/002667Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2014-01-16
Actavis Group PTC ehf	Zoledronic acid Actavis	zoledronic acid	EMEA/H/C/002488Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-04-20
Mylan Pharmaceuticals Limited	Zoledronic acid Mylan	zoledronic acid	EMEA/H/C/002482Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2012-08-23
Pfizer Europe MA EEIG	Zoledronic Acid Hospira	zoledronic acid	EMEA/H/C/0023654 mg / 5 ml and 4 mg / 100 ml:Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).5 mg / 100 ml:Treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.Treatment of Paget's disease of the bone in adults.	Authorised	yes	no	no	2012-11-19
Teva B.V.	Zoledronic acid Teva	zoledronic acid	EMEA/H/C/002439Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-08-16
Sandoz Pharmaceuticals d.d.	Aclasta	zoledronic acid	EMEA/H/C/000595Treatment of osteoporosis:, , , in post-menopausal women;, in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone.,	Authorised	no	no	no	2005-04-15

International Patents for ZOMETA

See the table below for patents covering ZOMETA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	75748
Australia	605778
Australia	7625687
Canada	1338895	DERIVES DE L'ACIDE DIPHOSPHONIQUE; METHODE DE PREPARATION ETCOMPOSITION PHARMACEUTIQUE A BASE DE CES DERIVES (DIPHOSPHONIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATIONTHEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM)
Czechoslovakia	266345	PROCESS FOR PREPARING NEW DERIVATIVES OF DIPHOSPHONIC ACID
Czechoslovakia	8705702

Supplementary Protection Certificates for ZOMETA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0258618	SPC/GB01/042	United Kingdom		PRODUCT NAME: ZOLEDRONIC ACID 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID; REGISTERED: CH 55463 20001128; UK EU/1/01/176/001 20010320; UK EU/1/01/176/002 20010320; UK EU/1/01/176/003 20010320
0258618	2001C/036	Belgium		PRODUCT NAME: ACIDE ZOLEDRONIQUE; NATL REGISTRATION NO/DATE: EU/1/01/176/001 20010321; FIRST REGISTRATION: CH 55463 20001128
0258618	C300059	Netherlands		PRODUCT NAME: ZOLEDRONINEZUUR, DESGEWENST IN DE VORM VAN EEN FARMACOLOGISCH A ANVAARDBAAR ZOUT OF HYDRAAT OF VAN EEN FARMACOLOGISCH AANVAARDB ARE ESTER MET EEN ALKANOL MET DE FORMULE ROH, WAARIN R C1-C4 AL KYL VOORSTELT, IN HET BIJZONDER ZOLEDRONINEZUUR-MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/01/176/001-EU/1/01/176/003 20010320
0258618	26/2001	Austria		PRODUCT NAME: ZOLEDRONSAEURE; NAT. REGISTRATION NO/DATE: EU/1/01/176/001-003 20010320; FIRST REGISTRATION: LI 55463 20001128
0275821	SPC/GB01/039	United Kingdom		PRODUCT NAME: ZOLEDRONIC ACID OPTIONALLY IN THE FORM OF A SALT THEREOF; NATIONAL REGISTRATION NO/DATE: EU/1/01/176/001-003 20010320; FIRST REGISTRATION: CH 55463 20001128
0275821	01C0035	France		PRODUCT NAME: ZOLEDRONIC ACID; NAT REG. NO/DATE: EU/1/01/176/001 20010320; FIRST REG.: LI IKS N 55 463 20001128

Last updated: July 30, 2026

Zometa (zoledronic acid) market dynamics and financial trajectory: sales trends, drivers, exclusivity, and competitive risks

Zometa (zoledronic acid) is a branded bisphosphonate used in oncology to prevent skeletal-related events (SREs) in metastatic bone disease. Financial trajectory since launch is shaped by (1) broad generic entry pressure once key exclusivities expired, (2) competitive dynamics from other bisphosphonates and denosumab, (3) shifting oncology practice patterns, and (4) the regulatory and payer environment governing SRE-prevention indications. The market has grown in underlying need, but brand revenue has been capped by generic substitution and pricing erosion.

---

How have Zometa sales evolved since launch and what is the current revenue trajectory?

Answer: Zometa’s branded revenues have declined materially over time as generic zoledronic acid products entered in the U.S., shifting the market from branded to largely generic units. Net sales trend is dominated by (a) loss of market share to lower-cost generics, (b) oncology payer reimbursement pressure, and (c) competition in SRE prevention from denosumab (Xgeva/Prolia) and alternative regimens.

What typically drives the branded sales curve

• Exclusivity rollover: branded sales peak while regulatory exclusivity blocks direct generic competition.
• Generic substitution: once multiple abbreviated new drug application (ANDA) products launch, pricing compresses quickly.
• Indication breadth vs. switching: Zometa covers major oncology SRE-prevention settings, but prescriber switching to lower total cost or preferred sequences accelerates replacement.
• Guideline and access: adoption of denosumab in certain settings impacts bisphosphonate share.

Sales-in-Use reality: “units” vs “net sales”

Even where SRE prevention demand stays stable, net sales fall as:

• weighted average wholesale acquisition cost declines after generic competition
• rebates and contracting shift toward lowest-cost supply options
• channel mix changes from single-source brand to multi-NDC generic supply

---

What market drivers increased demand for zoledronic acid while brand pricing fell?

Answer: Underlying demand for SRE prevention in metastatic solid tumors and multiple myeloma supports volume continuity, but branded pricing and margins compress once generics proliferate.

Demand-side drivers

• High incidence oncology populations: metastatic bone disease and multiple myeloma maintain a steady addressable market.
• Protocol-based use: once dosing schedules are standardized (IV zoledronic acid), clinicians often keep stable therapy to reduce visit burden.
• Safety and familiarity: clinicians have long experience with bisphosphonates, influencing inertia even as payer pressure increases.

Price and margin headwinds

• Generic reference pricing: in many jurisdictions, zoledronic acid becomes a “benchmark” generic basket product.
• Payer contracting: formulary tiering and bid processes favor the lowest priced NDC at scale.
• Alternative competition: denosumab has price and access negotiations of its own, but in certain subpopulations it has displaced bisphosphonates.

---

Which competitors most affect Zometa’s market dynamics in SRE prevention?

Answer: The main competitive set is (1) denosumab products for SRE prevention and (2) other bisphosphonates used in overlapping settings. The competitive pressure shows up as share loss in preferred-provider lists and oncology pathways.

Denosumab as the key cross-class competitor

• Xgeva (denosumab) is a central competitor for SRE prevention in metastatic bone disease.
• Clinical and practice factors: denosumab is used to reduce SRE risk in many protocols; payer access and guideline presence can tilt selection.

Other bisphosphonates

• Zoledronic acid competes with the bisphosphonate class in SRE prevention and related oncology supportive care pathways.
• Practically, switching costs are low once generics are available for zoledronic acid; the market then turns into a cost competition against both within-class and cross-class options.

---

How does generic entry risk shape Zometa’s financial performance?

Answer: Zometa’s branded financial trajectory is tightly linked to the timing and breadth of generic launches. Once multiple ANDAs launch, the brand loses prescription share quickly and pricing falls across the class.

What the generic substitution pathway typically looks like

• First-wave launches: early entrants trigger initial price breaks.
• Second-wave and NDC proliferation: additional ANDAs deepen price compression.
• Supply consolidation: in some countries, a few large generic suppliers dominate, further reducing pricing.

Paragraph IV and litigation impact

The key financial variable in the U.S. is the extent to which Orange Book listed patents delayed or accelerated generic entry via litigation or settlement-driven “launch calendars.” Without patent-by-patent Orange Book and court docket specifics, the net result for branded Zometa has been consistent: exclusivity loss leads to rapid erosion of branded net sales.

---

What is the Orange Book status of Zometa and how do listed patents affect launch timing?

Answer: Zometa is subject to Orange Book patent listing dynamics (drug substance and formulation and/or method-of-use) that historically governed generic entry timing. The current commercial reality is that branded exclusivity has largely been exhausted, allowing generic zoledronic acid products to compete.

How Orange Book typically governs zoledronic acid generics

• Drug substance and composition of matter patents historically create the exclusion period.
• Method-of-use or formulation patents can extend exclusivity at the edges if still in force, depending on the claim scope tied to the approved indication and dosage form.
• Market effect: if patent coverage is narrow or already expired, multiple generic launches proceed and compress pricing.

---

When does Zometa lose exclusivity in the major markets and what does that mean for brand vs. generic?

Answer: Zometa’s meaningful exclusivity windows have passed, and the market is now in a largely generic competitive phase in major markets where biosimilar-style mechanisms do not apply (zoledronic acid is chemically synthesized).

Brand vs. generic in a post-exclusivity world

• Brand: revenue becomes a residual share product, relying on contracting, patient assistance, and institutional preferences.
• Generic: volume captures the majority of prescriptions, with pricing anchored to competition and tender mechanics.

---

What formulations and dosage forms matter for competitive substitution and reimbursement?

Answer: Zometa’s core differentiation historically is the IV dosing presentation and dosing schedule aligned to the FDA-approved SRE-prevention indications. Generic substitution is enabled when ANDA products match reference product concentration, dosage form, route of administration, and labeling.

Substitution-relevant attributes

• IV preparation and administration workflow (hospital and infusion center operational fit)
• Pack size and NDC availability (affects contracting and procurement)
• Stability and handling (institutional preference after experience)
• Labeling parity (SRE-prevention wording and dosing schedule)

---

How do U.S. FDA regulatory pathway dynamics affect the competitive landscape for Zometa?

Answer: Generic zoledronic acid typically enters via ANDAs under the Hatch-Waxman framework once Orange Book blocking patents expire or are worked around. Post-entry, FDA regulatory status and labeling parity facilitate rapid substitution.

What matters for market access

• Bioequivalence and formulation match for ANDAs
• Manufacturing compliance affecting supply continuity
• Label alignment for dosing in oncology supportive care

---

What patent litigation and settlements have historically shaped Zometa’s commercial timeline?

Answer: Patent litigation historically influenced U.S. generic launch timing for zoledronic acid through Paragraph IV challenges to Orange Book-listed patents. The longer-term financial trajectory of the brand is consistent with eventual entry once the blocking set was neutralized.

How litigation translates into financial outcomes

• Stays and injunctions can delay launches and preserve brand unit share.
• Settlements can create “agreed entry dates” that extend branded revenue slightly but do not change the long-run substitution pattern after exclusivity ends.
• If multiple patents are challenged, generic entry can occur in waves, causing stepwise revenue declines.

---

How does Zometa compare with Xgeva for SRE prevention market share and payer impact?

Answer: Both target SRE prevention, but class differences matter in reimbursement and access. Denosumab’s market presence can divert demand within oncology supportive care, while zoledronic acid’s value proposition shifts to cost when generics are available.

Competitive implications

• When payers favor denosumab: bisphosphonate shares tighten, even if total SRE-prevention prescriptions rise.
• When payers favor low-cost zoledronic acid: generics expand share, but denosumab can retain positions where clinical pathways or contracting favor it.

---

What are the likely global commercial inflection points for Zometa going forward?

Answer: The dominant inflection points are procurement and contracting cycles for generic zoledronic acid and continued cross-class competition. Branded Zometa remains exposed to continued substitution unless a specific market maintains brand-preferred status via procurement rules or legacy contracts.

Key forward-looking risk factors

• Increased generic supply: lowers price floors.
• Tender-based procurement: increases payer leverage to drive discounts.
• Cross-class displacement: denosumab access changes can re-route prescribing.
• Institutional formularies: oncology supportive care committees influence brand survivability.

---

Key Takeaways

• Zometa’s financial trajectory has been dominated by the shift from branded exclusivity to generic zoledronic acid competition, driving sustained net sales erosion even if underlying SRE-prevention demand remains durable.
• Denosumab (Xgeva) is the major cross-class competitor affecting share in SRE prevention pathways, while other bisphosphonates provide within-class pressure.
• The market dynamic is primarily economic after exclusivity, with payer contracting, tender procurement, and supply continuity determining winners more than clinical differentiation.
• Patent and litigation events historically influence launch timing, but the post-exclusivity end-state is a largely generic market with pricing compression.

---

FAQs

1) Does Zometa still have meaningful branded revenue in the U.S. after generic competition?
Branded revenue is typically residual versus generic volumes and contracts; the dominant financial driver is pricing compression and channel substitution.

2) Is Zometa protected by new patents that can delay generics now?
Zometa’s commercial condition reflects that key blocking coverage has not maintained long-term exclusivity in major markets; current competition indicates generics are viable.

3) How does denosumab adoption change zoledronic acid prescribing in oncology?
Denosumab can displace bisphosphonates in certain protocols and payer arrangements, reducing zoledronic acid’s addressable share even when SRE-prevention volumes grow.

4) Do formulation differences matter for generic substitution of IV zoledronic acid?
Yes for procurement and handling, but substitution is largely governed by route of administration, dosage form, concentration, and labeling parity.

5) What risks exist for generic suppliers that could change Zometa’s pricing floor?
Manufacturing disruptions, quality-related supply constraints, and contracting shifts can temporarily lift pricing, but long-run competition tends to reset discounts.

---

References (APA)

No sources were provided in the prompt, and no citations were included because no verifiable market, FDA, or patent record data was supplied.

DrugChatter Q&A for ZOMETA

Zometa novartis patent expiration?
How much does zometa cost?
Zometa infusion side effects?
Zometa 4 mg injection price?
How much is zometa infusion?